Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression

Heterogeneous expression of melanocytic antigens occurs frequently in melanomas and represents a potent barrier to immunotherapy. We previously showed that coordinated losses of several melanocytic antigens are generally attributable to down-regulation of antigen gene expression rather than irreversible mutation. Treatment of melanoma cells with mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitors blocks ERK activation and increases steady-state levels of mRNAs and corresponding protein expression for the melanocytic antigens Melan-A/MART-1, gp100, and tyrosinase. Although the degree of MEK inhibitor enhancement of antigen expression varied among different cell lines irrespective of their antigen expression status, all showed detectable responses. Notably, the antigen-enhancing effects of the MEK inhibitors could not be attributed to the master melanocytic regulator MITF-M. Because MAPK pathway activation via constitutively active mutant forms of BRAF is common in melanomas, correlation between BRAF function and antigen expression was investigated. No simple correlation of endogenous BRAF mutational status and antigen levels was observed, but transient overexpression of V600E BRAF increased ERK activation and reduced Melan-A/MART-1 levels in antigen-positive cell lines. These data indicate that whereas multiple factors may regulate antigen expression in melanomas, enhancement of MAPK signaling can act as a negative influence. Blocking such signaling with MEK inhibitors accordingly augments antigen levels, thereby enhancing Melan-A/MART-1–specific cytotoxic T-cell responses to antigen-negative cells following MEK inhibition treatment. Consequently, MAPK inhibition may assist targeting of melanomas for immunotherapy. (Mol Cancer Res 2006;4(10):779–92)

[1]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[2]  R. Marais,et al.  Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation , 2005, The Journal of cell biology.

[3]  D. Schadendorf,et al.  Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. , 2005, Carcinogenesis.

[4]  Ming Zhou,et al.  Regulation of Raf-1 by direct feedback phosphorylation. , 2005, Molecular cell.

[5]  D. Bennett,et al.  UV-induced Expression of Key Component of the Tanning Process, the POMC and MC1R Genes, Is Dependent on the p-38-activated Upstream Stimulating Factor-1 (USF-1)* , 2004, Journal of Biological Chemistry.

[6]  T. Golub,et al.  Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. , 2004, Cancer cell.

[7]  J. Inazawa,et al.  Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines , 2004, Oncogene.

[8]  Y. Nishimura,et al.  B-Raf Contributes to Sustained Extracellular Signal-regulated Kinase Activation Associated with Interleukin-2 Production Stimulated through the T Cell Receptor* , 2004, Journal of Biological Chemistry.

[9]  Richard Marais,et al.  The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.

[10]  Mathew J Garnett,et al.  Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.

[11]  C. Marshall,et al.  B-RAF is a therapeutic target in melanoma , 2004, Oncogene.

[12]  E. Wattenberg,et al.  Mitogen-activated Protein Kinase Phosphatase-3 Is a Tumor Promoter Target in Initiated Cells That Express Oncogenic Ras* , 2004, Journal of Biological Chemistry.

[13]  J. Norman,et al.  B-Raf Acts via the ROCKII/LIMK/Cofilin Pathway To Maintain Actin Stress Fibers in Fibroblasts , 2004, Molecular and Cellular Biology.

[14]  Markus Ringnér,et al.  Microarray expression profiling in melanoma reveals a BRAF mutation signature , 2004, Oncogene.

[15]  G. Reifenberger,et al.  Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas , 2004, International journal of cancer.

[16]  C. Springer,et al.  V599EB-RAF is an Oncogene in Melanocytes , 2004, Cancer Research.

[17]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[18]  F. Haluska,et al.  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. , 2004, The Journal of investigative dermatology.

[19]  K. Eisenmann,et al.  Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. , 2003, Cancer research.

[20]  F. Mascarelli,et al.  Mutation of B-Raf in Human Choroidal Melanoma Cells Mediates Cell Proliferation and Transformation through the MEK/ERK Pathway* , 2003, Journal of Biological Chemistry.

[21]  J. Eriksson,et al.  Type-2A protein phosphatase activity is required to maintain death receptor responsiveness , 2003, Oncogene.

[22]  G. V. Vande Woude,et al.  Novel protein targeted therapy of metastatic melanoma. , 2003, Current pharmaceutical design.

[23]  S. Ramaswamy,et al.  MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. , 2003, The American journal of pathology.

[24]  C. Pritchard,et al.  Raf proteins and cancer: B-Raf is identified as a mutational target. , 2003, Biochimica et biophysica acta.

[25]  K. Smalley,et al.  A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? , 2003, International journal of cancer.

[26]  I. S. Dunn,et al.  Induction of "antigen silencing" in melanomas by oncostatin M: down-modulation of melanocyte antigen expression. , 2003, Molecular cancer research : MCR.

[27]  J. Aguirre-Ghiso,et al.  ERKMAPK Activity as a Determinant of Tumor Growth and Dormancy; Regulation by p38SAPK , 2003 .

[28]  D. Elder,et al.  Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. , 2003, Cancer research.

[29]  D. Morton,et al.  Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. , 2003, Cancer research.

[30]  J. Arbiser,et al.  Mitogen-actived protein kinase activation is an early event in melanoma progression. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[32]  G. Woude,et al.  Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  S. Carreira,et al.  The Usf‐1 transcription factor is a novel target for the stress‐responsive p38 kinase and mediates UV‐induced Tyrosinase expression , 2001, The EMBO journal.

[34]  I. S. Dunn,et al.  A Novel Autocrine Pathway of Tumor Escape from Immune Recognition: Melanoma Cell Lines Produce a Soluble Protein That Diminishes Expression of the Gene Encoding the Melanocyte Lineage Melan-A/MART-1 Antigen Through Down-Modulation of Its Promoter , 2001, The Journal of Immunology.

[35]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[36]  J. Sebolt-Leopold.  Development of anticancer drugs targeting the MAP kinase pathway , 2000, Oncogene.

[37]  K. Guan,et al.  Activation of B‐Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601 , 2000, The EMBO journal.

[38]  C. Goding,et al.  Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. , 2000, Genes & development.

[39]  S Shibahara,et al.  Regulation of pigment cell-specific gene expression by MITF. , 2000, Pigment cell research.

[40]  Y. Suzuki,et al.  T cell immune responses against melanoma and melanocytes in cancer and autoimmunity. , 2000, Pigment cell research.

[41]  V. Hearing.  The melanosome: the perfect model for cellular responses to the environment. , 2000, Pigment cell research.

[42]  K Takahashi,et al.  Structural organization of the human microphthalmia-associated transcription factor gene containing four alternative promoters. , 2000, Biochimica et biophysica acta.

[43]  D. Hunt,et al.  Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens , 2000, Cancer Immunology, Immunotherapy.

[44]  F. Marincola,et al.  Heterogeneity in expression of human leukocyte antigens and melanoma‐associated antigens in advanced melanoma , 2000, Journal of cellular physiology.

[45]  E. Price,et al.  c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. , 2000, Genes & development.

[46]  S. Pervaiz,et al.  Melanoma antigen recognition by tumour‐infiltrating T lymphocytes (TIL): effect of differential expression of Melan‐A/MART‐1 , 2000, Clinical and experimental immunology.

[47]  S. Steinberg,et al.  Immune selection after antigen-specific immunotherapy of melanoma. , 1999, Surgery.

[48]  Hishii,et al.  Studies of the mechanism of cytolysis by tumour‐infiltrating lymphocytes , 1999, Clinical and experimental immunology.

[49]  J. Wityak,et al.  MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. , 1998, Bioorganic & medicinal chemistry letters.

[50]  P. J. van den Elsen,et al.  The role of enhancer A in the locus-specific transactivation of classical and nonclassical HLA class I genes by nuclear factor kappa B. , 1998, Journal of immunology.

[51]  W. Kolch,et al.  Activated raf induces the hyperphosphorylation of stathmin and the reorganization of the microtubule network. , 1998, The Journal of biological chemistry.

[52]  F. Hobbs,et al.  Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.

[53]  A. Brunet,et al.  Inhibition of the Mitogen-activated Protein Kinase Pathway Triggers B16 Melanoma Cell Differentiation* , 1998, The Journal of Biological Chemistry.

[54]  L. Butterfield,et al.  Cloning and analysis of MART-1/Melan-A human melanoma antigen promoter regions. , 1997, Gene.

[55]  P. J. van den Elsen,et al.  In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[56]  F. Oesch,et al.  Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic‐T‐cell responses: Evidence for immunoselection of antigen‐loss variants in vivo , 1996, International journal of cancer.

[57]  Philip R. Cohen,et al.  PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.

[58]  A. Wolfman,et al.  Different structural requirements within the switch II region of the Ras protein for interactions with specific downstream targets. , 1995, Oncogene.

[59]  C. Figdor,et al.  Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[60]  J. Aguirre-Ghiso,et al.  ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). , 2003, Cancer research.

[61]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[62]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[63]  F. Marincola,et al.  Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity. , 1998, Critical reviews in immunology.

[64]  J. H. Pope,et al.  Human malignant melanoma cell lines. , 1979, Pathology.